Details of the Drug

General Information of Drug (ID: DMVGAI4)

Drug Name

DYN101

Indication

Disease Entry	ICD 11	Status	REF
Congenital structural myopathy	8C72.0	Phase 1/2	[1]
------------------------------------------------------------------------------------

Drug Type

Antisense oligonucleotide

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04033159) A Phase 1/2 Trial on the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of DYN101 in Patients >= 16 Years of Age With Centronuclear Myopathies Caused by Mutations in DNM2 or MTM1. U.S.National Institutes of Health.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight